Inventor
SHELDON CAO
Inventor
US
Overview
Patents· 4 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds15%
C07KPeptides15%
C07CAcyclic or carbocyclic compounds8%
PatentTitleYear
12,516,016GPX4 inhibitors, pharmaceutical compositions thereof, and their use for treating GPX4-mediated diseases202612,318,455Anti-HER2 antibody-drug conjugate and application thereof202511,998,534GPX4 inhibitor in combination with anticancer agent for treating proliferative disease202411,679,162Anti-5T4 antibody-drug conjugate and use thereof2023Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2023–2025Patents assigned to HANGZHOU ADCORIS BIOPHARMA CO LTD (2)· patent assignee history
2023–2025Based in CN· patent location history
2024Patents assigned to EUBULUS BIOTHERAPEUTICS INC (1)· patent assignee history
2024–2026Based in US· patent location history
2026Patents assigned to CAO SHELDON (1)· patent assignee history
2026Patents assigned to EUBULUS BIOTHERAPEUTICS HONG KONG LTD (1)· patent assignee history
2026Patents assigned to WANG XIAOLEI (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HANGZHOU ADCORIS BIOPHARMA CO LTD | 2 | 2023–2025 |
| CAO SHELDONself | 1 | 2026 |
| EUBULUS BIOTHERAPEUTICS HONG KONG LTD | 1 | 2026 |
| EUBULUS BIOTHERAPEUTICS INC | 1 | 2024 |
| WANG XIAOLEI | 1 | 2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 2 | 2024–2026 |
| CN | 2 | 2023–2025 |